View in EDS

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Saved in:
Bibliographic Details
Title: Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Authors: Robak, Tadeusz1 robaktad@csk.umed.lodz.pl, Jin, Jie2, Pylypenko, Halyna3, Verhoef, Gregor4, Siritanaratkul, Noppadol5, Drach, Johannes6, Raderer, Markus7, Mayer, Jiri8, Pereira, Juliana9, Tumyan, Gayane10, Okamoto, Rumiko11, Nakahara, Susumu12, Hu, Peter13, Appiani, Carlos13, Nemat, Sepideh14, Cavalli, Franco15, LYM-3002 investigators
Source: Lancet Oncology. Nov2018, Vol. 19 Issue 11, p1449-1458. 10p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(18)30685-5